Soft Tissue Sarcoma (STS) Clinical Trials

14 recruitingLast updated: June 17, 2026

There are 14 actively recruiting soft tissue sarcoma (sts) clinical trials across 12 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1. Top locations include Guangzhou, Guangdong, China, Cleveland, Ohio, United States, Dongguan, China. Updated daily from ClinicalTrials.gov.


Soft Tissue Sarcoma (STS) Trials at a Glance

14 actively recruiting trials for soft tissue sarcoma (sts) are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Cleveland, and Dongguan. Lead sponsors running soft tissue sarcoma (sts) studies include Sun Yat-sen University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, and GI Innovation, Inc..

Browse soft tissue sarcoma (sts) trials by phase

Treatments under study

About Soft Tissue Sarcoma (STS) Clinical Trials

Looking for clinical trials for Soft Tissue Sarcoma (STS)? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Soft Tissue Sarcoma (STS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Soft Tissue Sarcoma (STS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Not Applicable

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Urothelial CarcinomaCervical CarcinomaCutaneous Melanoma+7 more
Institut Claudius Regaud450 enrolled1 locationNCT06967961
Recruiting
Phase 1

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

OsteosarcomaSoft Tissue Sarcoma (STS)
Sun Yat-sen University16 enrolled1 locationNCT07648069
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 2

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

OsteosarcomaSoft Tissue Sarcoma (STS)
Sun Yat-sen University57 enrolled1 locationNCT07602049
Recruiting
Not Applicable

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma (STS)
Shandong Cancer Hospital and Institute106 enrolled1 locationNCT06980259
Recruiting
Phase 2

Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

Soft Tissue Sarcoma (STS)
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas25 enrolled1 locationNCT07032285
Recruiting
Phase 2

BAL Fluid Biomarkers in Sarcoma

Soft Tissue Sarcoma (STS)Bronchoalveolar Lavage (BAL)Bronchoalveolar Lavage Fluid
University Health Network, Toronto70 enrolled1 locationNCT06815666
Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

SarcomaAngiosarcomaSoft Tissue Sarcoma (STS)+9 more
Royal Marsden NHS Foundation Trust800 enrolled1 locationNCT07432932
Recruiting
Phase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSynovial Sarcomas+7 more
Oslo University Hospital40 enrolled2 locationsNCT07173972
Recruiting
Early Phase 1

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Breast CancerBladder CarcinomaEsophageal Carcinoma+11 more
Var2 Pharmaceuticals32 enrolled1 locationNCT06645808
Recruiting
Not Applicable

SAVE Studie- SArcoma Surgery With Vacuum Enhanced Wound Treatment Randomised Study to Evaluate the Wound Management in Sarcoma Surgery

Soft Tissue Sarcoma (STS)
Universitätsklinikum Hamburg-Eppendorf100 enrolled1 locationNCT06889532
Recruiting
Not Applicable

Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study

Soft Tissue Sarcoma (STS)
Sun Yat-sen University40 enrolled2 locationsNCT06848582
Recruiting

Development of a Radiomics Model With MR to Predict the Occurence of a Infiltration of Muscoskeletal Tumor

Soft Tissue Sarcoma (STS)Bone Cancer Tumor
IRCCS Azienda Ospedaliero-Universitaria di Bologna122 enrolled1 locationNCT06774729
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

HER2-negative Breast CancerAdvanced Solid TumorMetastatic Solid Tumor+6 more
GI Innovation, Inc.358 enrolled11 locationsNCT05824975